Optimising the IgG‐degrading enzyme treatment regimen for enhanced adeno‐associated virus transduction in the presence of neutralising antibodies

OBJECTIVE: Pre‐existing neutralising antibodies (NAbs) to adeno‐associated viruses (AAVs) remain an impediment for systemically administered AAV‐mediated gene therapy treatment in many patients, and various strategies are under investigation to overcome this limitation. Here, IgG‐degrading enzymes (...

Descripción completa

Detalles Bibliográficos
Autores principales: Ros‐Gañán, Irene, Hommel, Mirja, Trigueros‐Motos, Laia, Tamarit, Blanche, Rodríguez‐García, Estefanía, Salas, David, Pérez, Guiomar, Douar, Anne, Combal, Jean Philippe, Benichou, Bernard, Ferrer, Veronica, González‐Aseguinolaza, Gloria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8867416/
https://www.ncbi.nlm.nih.gov/pubmed/35228870
http://dx.doi.org/10.1002/cti2.1375

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8867416/
https://www.ncbi.nlm.nih.gov/pubmed/35228870
http://dx.doi.org/10.1002/cti2.1375

Ejemplares similares